Clinical Pharmacokinetics of Candesartan
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 41 (1) , 7-17
- https://doi.org/10.2165/00003088-200241010-00002
Abstract
Candesartan cilexetil is the prodrug of candesartan, an angiotensin II type 1 (AT1) receptor antagonist. Absorbed candesartan cilexetil is completely metabolised to candesartan. Oral bioavailability...Keywords
This publication has 29 references indexed in Scilit:
- Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and designJournal of Cardiac Failure, 1999
- Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart FailureCirculation, 1999
- Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysisBritish Journal of Clinical Pharmacology, 1999
- Candesartan Cilexetil: Comparison of once-daily versus twice-daily administration for systemic hypertensionClinical Therapeutics, 1999
- Effective dose range of Candesartan cilexetil for systemic hypertensionThe American Journal of Cardiology, 1999
- Angiotensin II antagonism and plasma radioreceptor‐kinetics of candesartan in manBritish Journal of Clinical Pharmacology, 1998
- Candesartan CilexetilDrugs, 1998
- Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor AntagonistsClinical Pharmacokinetics, 1997
- Characterization of the Angiotensin II Receptor Antagonist TCV-116 in Healthy VolunteersHypertension, 1995
- Cardiovascular and Renal Review: Pharmacology of Angiotensin II Receptor Antagonists: Comparison with Renin Inhibitors and Angiotensin-Converting Enzyme InhibitorsExpert Opinion on Investigational Drugs, 1994